The SMARCA4/SMARCA2 allosteric inhibitor, FHD-286, effectively suppressed the proliferation of a broad collection of patient-derived AML cells, promoted differentiation, and decreased tumor growth in vivo [125]. The gene discussed is SMARCA2; the disease is acute myeloid leukemia.